Systemic Inflammatory Pattern of Patients With Community-Acquired Pneumonia With and Without COPD

被引:61
作者
Crisafulli, Ernesto [1 ]
Menendez, Rosario [2 ]
Huerta, Arturo [3 ]
Martinez, Raquel [2 ]
Montull, Beatriz [2 ]
Clini, Enrico [1 ]
Torres, Antoni [3 ]
机构
[1] Univ Modena & Reggio Emilia, Osped Villa Pineta, Dept Pulm Rehabil, Modena, Italy
[2] CIBERES, Hosp Univ & Politecnico La Fe, Serv Neumol, Valencia, Spain
[3] Univ Barcelona, Dept Pneumol, Hosp Clin Barcelona, Clin Inst Thorax,Inst Invest Biomed August Pi & S, Barcelona, Spain
关键词
OBSTRUCTIVE PULMONARY-DISEASE; TREATMENT FAILURE; RISK-FACTORS; PROCALCITONIN; PHAGOCYTOSIS; PREDICTION; BIOMARKERS; MORTALITY; SEVERITY; ACTIVATION;
D O I
10.1378/chest.12-1684
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Background: Several clinical studies have evaluated the role of COPD in patients with community-acquired pneumonia (CAP). We investigated the systemic inflammatory response of patients with CAP (CAP + COPD) and patients without associated COPD (CAP only). Methods: Clinical, microbiologic, and immunologic data were collected from 367 prospective patients on admission to hospital during a 3-year period. Comparative analyses were performed between patients with CAP + COPD (n = 117) and those with CAP only (n = 250) and between patients with and without domiciliary use of inhaled corticosteroids (ICSs) and oral corticosteroids. Results: Detailed characteristics of clinical severity and prognosis (mortality on hospitalization and at 30 and 90 days) were similar between the CAP + COPD and CAP-only groups. The readmission rate and the frequency of previous pneumonia were higher in the group of patients with CAP + COPD. On day 1 (admission to hospital), patients with CAP + COPD had significantly lower serum levels of tumor necrosis factor-alpha, IL-1, and IL-6 compared with the CAP-only group; levels of the remaining inflammatory biomarkers (C-reactive protein, procalcitonin, IL-8, and IL-10) were similar at days 1 and 3. The exclusion of patients with domiciliary use of ICS and oral corticosteroids confirmed lower levels of TNF-alpha on day 1 in patients with CAP + COPP. Finally, lower levels of IL-6 were found only among those patients with COPD who were currently using ICS. Conclusions: Our prospective study demonstrates a different, disease-specific, early inflammatory pattern between patients with CAP with and without associated COPD. These findings are not completely corticosteroid mediated. CHEST 2013; 143(4):1009-1017
引用
收藏
页码:1009 / 1017
页数:9
相关论文
共 42 条
[21]   Severity and outcomes of hospitalised community-acquired pneumonia in COPD patients [J].
Liapikou, A. ;
Polverino, E. ;
Ewig, S. ;
Cilloniz, C. ;
Marcos, M. A. ;
Mensa, J. ;
Bello, S. ;
Martin-Loeches, I. ;
Menendez, R. ;
Torres, A. .
EUROPEAN RESPIRATORY JOURNAL, 2012, 39 (04) :855-861
[22]   Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study [J].
Lim, WS ;
van der Eerden, MM ;
Laing, R ;
Boersma, WG ;
Karalus, N ;
Town, GI ;
Lewis, SA ;
Macfarlane, JT .
THORAX, 2003, 58 (05) :377-382
[23]   Markers of treatment failure in hospitalised community acquired pneumonia [J].
Menendez, R. ;
Cavalcanti, M. ;
Reyes, S. ;
Mensa, J. ;
Martinez, R. ;
Marcos, M. A. ;
Filella, X. ;
Niederman, M. ;
Torres, A. .
THORAX, 2008, 63 (05) :447-452
[24]   Risk factors of treatment failure in community acquired pneumonia:: implications for disease outcome [J].
Menéndez, R ;
Torres, A ;
Zalacaín, R ;
Aspa, J ;
Villasclaras, JJM ;
Borderías, L ;
Moya, JMB ;
Ruiz-Manzano, J ;
de Castro, FR ;
Blanquer, J ;
Pérez, D ;
Puzo, C ;
Gascón, FS ;
Gallardo, J ;
Alvarez, C ;
Molinos, L .
THORAX, 2004, 59 (11) :960-965
[25]   Stability in community-acquired pneumonia: one step forward with markers? [J].
Menendez, R. ;
Martinez, R. ;
Reyes, S. ;
Mensa, J. ;
Polverino, E. ;
Filella, X. ;
Esquinas, C. ;
Martinez, A. ;
Ramirez, P. ;
Torres, A. .
THORAX, 2009, 64 (11) :987-992
[26]   Biomarkers improve mortality prediction by prognostic scales in community-acquired pneumonia [J].
Menendez, R. ;
Martinez, R. ;
Reyes, S. ;
Mensa, J. ;
Filella, X. ;
Marcos, M. A. ;
Martinez, A. ;
Esquinas, C. ;
Ramirez, P. ;
Torres, A. .
THORAX, 2009, 64 (07) :587-591
[27]   Community-acquired pneumonia in patients with and without chronic obstructive pulmonary disease [J].
Molinos, L. ;
Clemente, M. G. ;
Miranda, B. ;
Alvarez, C. ;
del Busto, B. ;
Cocina, B. R. ;
Alvarez, F. ;
Gorostidi, J. ;
Orejas, C. .
JOURNAL OF INFECTION, 2009, 58 (06) :417-424
[28]   Role of glucocorticoids on inflammatory response in nonimmunosuppressed patients with pneumonia:: a pilot study [J].
Montón, C ;
Ewig, S ;
Torres, A ;
El-Ebiary, M ;
Filella, X ;
Rañó, A ;
Xaubet, A .
EUROPEAN RESPIRATORY JOURNAL, 1999, 14 (01) :218-220
[29]   The natural history of community-acquired pneumonia in COPD patients: A population database analysis [J].
Muellerova, Hana ;
Chigbo, Chuba ;
Hagan, Gerry W. ;
Woodhead, Mark A. ;
Miravitlles, Marc ;
Davis, Kourtney J. ;
Wedzicha, Jadwiga A. .
RESPIRATORY MEDICINE, 2012, 106 (08) :1124-1133
[30]   Novel nonantibiotic therapies for pneumonia - Cytokines and host defense [J].
Nelson, S .
CHEST, 2001, 119 (02) :419S-425S